About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Category Archives: Pricing and Value
The Growing Profile and Influence of ICER
The year began with a prediction from Senator Mitt Romney to pharmaceutical executives that “change is coming”. There have been high profile hearings on the topic in the Congress and legislation that moved in both the Senate and the House … Continue reading
Posted in Pharma Industry Image, Pricing and Value
Tagged ICER, Pharma, pharmaceutical pricing
Comments Off on The Growing Profile and Influence of ICER
In the Pharma Pricing Debate, We Are Talking About More Than Apples and Oranges
This week the Senate Finance Committee held the second in what will be four hearings on the price of pharmaceutical drugs – Drug Pricing in America: A Prescription for Change. The first hearing, on January 29, listened to a panel … Continue reading
Posted in Pharma Industry Image, Pricing and Value
Comments Off on In the Pharma Pricing Debate, We Are Talking About More Than Apples and Oranges
Guidance on Social Media – But Not the One You Think….
Last week the bookstore Borders announced that it would be liquidating its remaining stores. On the PBS News Hour, Jeffrey Brown spoke with Slate’s Annie Lowry about the giant chain went from having huge box bookstores to the end of … Continue reading
Posted in New and Social Media, Pricing and Value
6 Comments
Kaiser Report on HIV/AIDS and Medicare Part D
Relating to today’s earlier post on Ryan White reauthorization, another source of support for people with HIV has been Medicare. Today the Kaiser Family Foundation released a report on Medicare Part D and how people with HIV are faring under … Continue reading
Posted in Pricing and Value
Comments Off on Kaiser Report on HIV/AIDS and Medicare Part D
In Medicare Part D Failures, an Opportunity
As has been long awaited and discussed herein, many elderly are reaching the Medicare Part Donut-hole as evidenced by articles in both the Sunday New York Times and the Washington Post. Both papers profile and document the surprise and fear … Continue reading
Posted in Pharma Industry Image, Pricing and Value
Comments Off on In Medicare Part D Failures, an Opportunity